Phase I/II trial of decitabine as a sensitizer to carboplatin in platinum resistant recurrent ovarian cancer.
Phase of Trial: Phase I/II
Latest Information Update: 07 Oct 2014
At a glance
- Drugs Carboplatin (Primary) ; Decitabine (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 19 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 Oct 2012 Planned End Date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.